Under the deal, Exosome will provide its platforms that span across both nucleic acid and protein, including Shahky exosomal protein capture and quantitative analysis instrument.

Shahky instrument holds capacity to generate a high signal above the noise by selectively targeting disease specific exosomes. It will also remove background that is non-relevant to the disease.

According to Exosome, Shahky’s performance has been tested and validated in a leading Boston Hospital in early January of 2017.

The instrument can discover, assess and validate clinical biomarker that has been developed and monitored by Exosome’s regulatory department.

Shahky’s design control and engineering practices are in accordance with FDA and other applicable regulations.

Exosome Diagnostics business development head Mario Morken said: “We are excited to bring first of its kind technologies, such as Shahky, to our partners. The Shahky instrument represents a disruptive technology for drug development and ultimately the clinic.

Exosome Diagnostics president and CEO John Boyce said: “We are extremely pleased to announce this agreement with Merck KGaA, Darmstadt, Germany, as this represents a partnership that leverages both the centralized and de-centralized business models of Exosome Diagnostics, in order to bridge the gap between discovery and the clinic for liquid biopsies.”